SCHEMBL10150308

SCHEMBL10150308

CCOC(=O)N1CCN(c2nc(-c3ccccc3O)nc3c2CC[C@@H](C)C3)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 5/20 0.46
SMYD3 Q9H7B4 2/20 0.46
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
TSHR P16473 1/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 2/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ADRB2 P07550 1/20 0.41
ALDH1A1 P00352 4/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150332 0.93 GAA (0.50) GAASMN1; SMN2MAPTSMYD3KMT2A
SCHEMBL10150352 0.89 GAA (0.47) GAASMN1; SMN2MAPTSMYD3KMT2A
SCHEMBL10150354 0.84 KMT2A (0.41) MAPTKMT2AMEN1CNR1CNR2
SCHEMBL8299287 0.83 MEN1 (0.57) MAPTKMT2AMEN1TSHRKDM4E
SCHEMBL10150299 0.83 ALDH1A1 (0.53) MAPTKMT2AMEN1TSHRKDM4E
SCHEMBL10150306 0.83 SMAD3 (0.53) MAPTKMT2AMEN1TSHRKDM4E
SCHEMBL8297579 0.83 ALDH1A1 (0.53) MAPTKMT2AMEN1TSHRKDM4E
SCHEMBL8297570 0.83 SMAD3 (0.53) MAPTKMT2AMEN1TSHRKDM4E
SCHEMBL8299612 0.82 ALDH1A1 (0.42) MAPTKMT2AMEN1CNR1CNR2
SCHEMBL10150291 0.82 SMAD3 (0.52) MAPTKMT2AMEN1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 GAA 1215/4885SMN1; SMN2 662/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.